VisionPoint Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

VisionPoint Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$330K	Buy	631 +152	+32%	+$77.8K	0.05%	320
2026 Q2	$238K	Sell	479 -285	-37%	-$126K	0.04%	414
2026 Q1	$341K	Sell	764 -38	-5%	-$17.7K	0.06%	294
2025 Q4	$364K	Buy	+802	New	+$346K	0.07%	265
2025 Q3	–	Sell	-520	Closed	-$232K	–	416
2025 Q2	$232K	Buy	+520	New	+$240K	0.05%	321
2024 Q3	–	Sell	-75	Closed	-$35.2K	–	769
2024 Q2	$35.2K	Buy	75 +24	+47%	+$10.4K	0.01%	328
2024 Q1	$21.3K	Buy	+51	New	+$21.6K	0.01%	374

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

VisionPoint Advisory Group's VRTX Position: Q3 2026 in Review

VisionPoint Advisory Group increased its Vertex Pharmaceuticals (VRTX) stake by 32% in Q3 2026, buying an estimated $77.8K and bringing the position to 631 shares worth $330K. The position accounts for 0.05% of the portfolio, ranked #320.

VisionPoint Advisory Group first reported a position in VRTX in Q1 2024 and has held it in 7 quarters since. The position peaked at $364K in Q4 2025. 302 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

VisionPoint Advisory Group held 631 shares of Vertex Pharmaceuticals worth $330K as of Q3 2026.
VisionPoint Advisory Group bought 152 Vertex Pharmaceuticals shares in Q3 2026, an estimated $77.8K.
Vertex Pharmaceuticals made up 0.05% of VisionPoint Advisory Group's portfolio in Q3 2026, its #320 holding.
VisionPoint Advisory Group first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
VisionPoint Advisory Group's Vertex Pharmaceuticals position peaked at $364K in Q4 2025.
302 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on VisionPoint Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.